Prediction of Postoperative Recurrence in Crohn's Disease
Prediction Model and Molecular Mechanisms of Postoperative Recurrence in Crohn's Disease
This multicenter prospective observational cohort study aims to develop and validate a multimodal prediction model for postoperative recurrence in patients with Crohn's disease.
Patients with Crohn's disease who undergo intestinal resection will be enrolled and followed after surgery. Residual surgical tissue that would otherwise be discarded, together with routinely collected clinical data and biological samples, will be used for research. Multi-omics analyses, including single-cell transcriptomics and spatial transcriptomics, will be performed to identify biological features associated with postoperative recurrence.
Participants with Crohn's disease will be followed for clinical, endoscopic, and imaging recurrence after surgery. The study will use data from a screening cohort to develop a prediction model and a validation cohort to evaluate the performance of the model. A control group consisting of patients undergoing intestinal resection for conditions such as colorectal tumors or diverticular disease will also be included for comparative molecular analyses.
No treatment will be assigned by the study protocol. All treatment decisions will be made by the treating physicians according to routine clinical practice.
研究概览
详细说明
Crohn's disease is characterized by chronic relapsing intestinal inflammation, and a substantial proportion of patients eventually require intestinal resection because of complications such as strictures, penetrating disease, or failure of medical therapy. Postoperative recurrence remains common, but reliable biomarkers and validated prediction models for identifying patients at high risk of recurrence are still lacking.
This is a multicenter, prospective, observational cohort study designed to investigate the predictors and molecular mechanisms of postoperative recurrence in Crohn's disease. The study consists of a screening cohort and a validation cohort. Approximately 200 patients with Crohn's disease undergoing intestinal resection will be enrolled, including 100 participants in the screening cohort and 100 participants in the validation cohort. In addition, approximately 50 patients undergoing intestinal resection for colorectal tumors, diverticular disease, or other non-inflammatory bowel disease conditions will be enrolled as controls.
In the screening cohort, residual surgical specimens that would otherwise be discarded will be collected. Clinical characteristics, follow-up information, biological samples, and multi-omics data will also be collected. Molecular profiling will include analyses such as bulk transcriptomics, single-cell transcriptomics, spatial transcriptomics, proteomics, microbiome analysis, and metabolomics, as applicable. Differences between patients with and without postoperative recurrence will be evaluated, and machine-learning methods will be used to construct a multimodal prediction model.
The validation cohort will be used to evaluate the predictive performance of the multimodal model in a multicenter setting. Postoperative recurrence will be assessed using clinical, endoscopic, and imaging evaluations during follow-up. The study also aims to investigate molecular pathways associated with postoperative recurrence and to identify potential therapeutic targets.
This study is observational. No randomized assignment or protocol-mandated treatment will be provided. Clinical management and postoperative treatment decisions will be made independently by the treating physicians according to routine clinical practice.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Xiang Gao, MD
- 电话号码:+86-13502405878
- 邮箱:gxiang@mail.sysu.edu.cn
学习地点
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510655
- 招聘中
- The Sixth Affiliated Hospital, Sun Yat-sen University
-
接触:
- Xiang Gao, MD
- 电话号码:+86-13502405878
- 邮箱:gxiang@mail.sysu.edu.cn
-
接触:
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
取样方法
研究人群
描述
Inclusion Criteria:
Crohn's Disease Cohorts:
- Diagnosis of Crohn's disease according to the diagnostic criteria of the Chinese Consensus on Diagnosis and Treatment of Inflammatory Bowel Disease (2018, Beijing).
- Patients with Crohn's disease who require surgical resection of the diseased intestinal segment because of complications such as stricturing or penetrating disease, or because of failure of medical therapy.
Non-IBD Control Cohort:
1.Patients who require surgical resection of an intestinal segment because of conditions such as colorectal tumors or diverticular disease.
Exclusion Criteria:
Crohn's Disease Cohorts:
- Uncertain diagnosis of Crohn's disease.
- Clinical history or medical records are substantially incomplete, making it impossible to determine the time of recurrence or whether postoperative recurrence occurred.
Non-IBD Control Cohort:
- Coexisting inflammatory bowel disease or other rheumatic or autoimmune diseases.
- Substantially incomplete clinical history or medical records.
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Screening Cohort
Patients with Crohn's disease undergoing clinically indicated intestinal resection.
Approximately 100 participants will be enrolled in this cohort.
Residual surgical tissue, clinical characteristics, biological samples, and multi-omics data will be collected.
Participants will be followed after surgery to identify clinical, endoscopic, and imaging recurrence.
Data from this cohort will be used to identify molecular features associated with postoperative recurrence and to develop a multimodal prediction model.
|
Participants undergo intestinal resection as clinically indicated as part of routine medical care.
The surgical procedure is not assigned by the study protocol.
Residual surgical tissue that would otherwise be discarded may be collected for research analyses.
Residual surgical tissue and biological samples are collected for research.
Surgical tissue used for research consists of residual specimens remaining after routine clinical pathological examination.
Samples may be used for transcriptomic, single-cell transcriptomic, spatial transcriptomic, proteomic, microbiome, metabolomic, and other multi-omics analyses.
|
|
Validation Cohort
Patients with Crohn's disease undergoing clinically indicated intestinal resection.
Approximately 100 participants will be enrolled in this multicenter validation cohort and followed after surgery.
Clinical, endoscopic, imaging, and biological data will be collected to evaluate the predictive performance of the multimodal model developed in the screening cohort.
|
Participants undergo intestinal resection as clinically indicated as part of routine medical care.
The surgical procedure is not assigned by the study protocol.
Residual surgical tissue that would otherwise be discarded may be collected for research analyses.
Residual surgical tissue and biological samples are collected for research.
Surgical tissue used for research consists of residual specimens remaining after routine clinical pathological examination.
Samples may be used for transcriptomic, single-cell transcriptomic, spatial transcriptomic, proteomic, microbiome, metabolomic, and other multi-omics analyses.
|
|
Non-IBD Control Cohort
Patients without inflammatory bowel disease who undergo clinically indicated intestinal resection for conditions such as colorectal tumors or diverticular disease.
Approximately 50 participants will be enrolled.
Residual surgical tissue that would otherwise be discarded will be collected for comparative molecular and multi-omics analyses.
|
Participants undergo intestinal resection as clinically indicated as part of routine medical care.
The surgical procedure is not assigned by the study protocol.
Residual surgical tissue that would otherwise be discarded may be collected for research analyses.
Residual surgical tissue and biological samples are collected for research.
Surgical tissue used for research consists of residual specimens remaining after routine clinical pathological examination.
Samples may be used for transcriptomic, single-cell transcriptomic, spatial transcriptomic, proteomic, microbiome, metabolomic, and other multi-omics analyses.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Clinical Recurrence Rate at 6 Months
大体时间:6 months after intestinal resection
|
Clinical recurrence is defined as the recurrence of clinical manifestations or complications such as abdominal pain, diarrhea, hematochezia, fistula, or perforation, together with a Harvey-Bradshaw Index (HBI) >4 or Crohn's Disease Activity Index (CDAI) >150, with recurrence confirmed by endoscopic or imaging assessment.
The outcome is reported as the proportion of participants with clinical recurrence.
|
6 months after intestinal resection
|
|
Endoscopic Recurrence Rate at 6 Months
大体时间:6 months after intestinal resection
|
Endoscopic recurrence is defined as a Rutgeerts score of i2 or higher on postoperative endoscopy after complete resection of macroscopically diseased bowel.
The outcome is reported as the proportion of participants meeting the criterion for endoscopic recurrence.
|
6 months after intestinal resection
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Endoscopic Recurrence Rate at 1 Year
大体时间:1 year after intestinal resection
|
Endoscopic recurrence is defined as a Rutgeerts score of i2 or higher on postoperative endoscopy after complete resection of macroscopically diseased bowel.
The outcome is reported as the proportion of participants meeting the criterion for endoscopic recurrence.
|
1 year after intestinal resection
|
|
Clinical Recurrence Rate at 1 Year
大体时间:1 year after intestinal resection
|
Clinical recurrence is defined as recurrence of clinical manifestations or complications such as abdominal pain, diarrhea, hematochezia, fistula, or perforation, together with a Harvey-Bradshaw Index (HBI) >4 or Crohn's Disease Activity Index (CDAI) >150, with recurrence confirmed by endoscopic or imaging assessment.
The outcome is reported as the proportion of participants with clinical recurrence.
|
1 year after intestinal resection
|
|
Imaging Recurrence Rate at 1 Year
大体时间:1 year after intestinal resection
|
Imaging recurrence is defined as a score of 2 or higher on computed tomography enterography (CTE) or magnetic resonance enterography (MRE) after surgical resection of the diseased bowel.
The outcome is reported as the proportion of participants meeting the imaging recurrence criterion.
|
1 year after intestinal resection
|
|
Imaging Recurrence Rate at 6 Months
大体时间:6 months after intestinal resection
|
Imaging recurrence is defined as a score of 2 or higher on computed tomography enterography (CTE) or magnetic resonance enterography (MRE) after surgical resection of the diseased bowel.
The outcome is reported as the proportion of participants meeting the imaging recurrence criterion.
|
6 months after intestinal resection
|
|
Reoperation or Endoscopic Treatment Rate at 1 Year
大体时间:1 year after intestinal resection
|
The outcome is defined as the proportion of participants who require repeat intestinal resection or endoscopic treatment because of Crohn's disease recurrence after the index intestinal resection.
Stoma reversal procedures and surgeries for perianal disease are not counted as outcome events.
|
1 year after intestinal resection
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- G2025005
- 2025ZSLYEC-290 (其他标识符:Ethics Committee of The Sixth Affiliated Hospital, Sun Yat-sen University)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.